scholarly journals Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons

2022 ◽  
Vol 14 (1) ◽  
pp. 163-180
Author(s):  
Yi Luo ◽  
Fei Teng ◽  
Hong Fu ◽  
Guo-Shan Ding
2010 ◽  
Vol 48 (05) ◽  
Author(s):  
A Finkenstedt ◽  
I Graziadei ◽  
H Zoller ◽  
K Nachbaur ◽  
W Mark ◽  
...  

2018 ◽  
Vol 56 (01) ◽  
pp. E2-E89
Author(s):  
G Wiltberger ◽  
U Lange ◽  
H Hau ◽  
D Seehofer ◽  
F Krenzien ◽  
...  

2004 ◽  
Vol 42 (05) ◽  
Author(s):  
V Stadlbauer ◽  
S Schaffellner ◽  
D Kniepeiss ◽  
E Jakoby ◽  
F Iberer ◽  
...  

2020 ◽  
Vol 1 (19) ◽  
pp. 39-46
Author(s):  
T. V. Pinchuk ◽  
N. V. Orlova ◽  
T. G. Suranova ◽  
T. I. Bonkalo

At the end of 2019, a new coronavirus (SARS-CoV-2) was discovered in China, causing the coronavirus infection COVID-19. The ongoing COVID-19 pandemic poses a major challenge to health systems around the world. There is still little information on how infection affects liver function and the significance of pre-existing liver disease as a risk factor for infection and severe COVID-19. In addition, some drugs used to treat the new coronavirus infection are hepatotoxic. In this article, we analyze data on the impact of COVID-19 on liver function, as well as on the course and outcome of COVID-19 in patients with liver disease, including hepatocellular carcinoma, or those on immunosuppressive therapy after liver transplantation.


Sign in / Sign up

Export Citation Format

Share Document